Pyridam Farma Past Earnings Performance
Past criteria checks 0/6
Pyridam Farma has been growing earnings at an average annual rate of 37.4%, while the Pharmaceuticals industry saw earnings growing at 11.6% annually. Revenues have been growing at an average rate of 27.6% per year.
Key information
37.4%
Earnings growth rate
37.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 20.4% |
| Revenue growth rate | 27.6% |
| Return on equity | -23.9% |
| Net Margin | -12.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Pyridam Farma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 702,068 | -85,221 | 303,147 | 0 |
| 30 Sep 23 | 684,977 | -58,782 | 275,927 | 0 |
| 30 Jun 23 | 721,928 | 229,734 | 313,600 | 0 |
| 31 Mar 23 | 707,846 | 260,664 | 294,282 | 0 |
| 31 Dec 22 | 715,425 | 275,241 | 286,433 | 0 |
| 30 Sep 22 | 775,078 | 278,272 | 287,735 | -573 |
| 30 Jun 22 | 715,132 | 3,165 | 245,819 | 0 |
| 31 Mar 22 | 685,557 | -2,877 | 235,143 | 0 |
| 31 Dec 21 | 630,530 | 5,479 | 219,977 | 0 |
| 30 Sep 21 | 488,496 | 21,948 | 175,207 | 573 |
| 30 Jun 21 | 378,335 | 27,773 | 147,743 | 0 |
| 31 Mar 21 | 315,777 | 28,590 | 133,448 | 0 |
| 31 Dec 20 | 277,398 | 22,104 | 134,340 | 0 |
| 30 Sep 20 | 257,674 | 20,539 | 140,348 | 0 |
| 30 Jun 20 | 247,321 | 13,275 | 131,853 | 0 |
| 31 Mar 20 | 262,331 | 11,823 | 136,496 | 0 |
| 31 Dec 19 | 247,115 | 9,343 | 129,282 | 0 |
| 30 Sep 19 | 249,644 | 9,070 | 133,995 | 0 |
| 30 Jun 19 | 248,913 | 8,505 | 133,832 | 0 |
| 31 Mar 19 | 249,405 | 8,697 | 136,589 | 0 |
| 31 Dec 18 | 250,446 | 8,447 | 137,379 | 0 |
| 30 Sep 18 | 240,127 | 6,303 | 131,081 | 0 |
| 30 Jun 18 | 239,267 | 7,604 | 131,601 | 0 |
| 31 Mar 18 | 235,944 | 7,453 | 128,612 | 0 |
| 31 Dec 17 | 223,002 | 7,127 | 122,523 | 0 |
| 30 Sep 17 | 225,293 | 7,431 | 124,247 | 0 |
| 30 Jun 17 | 210,135 | 3,729 | 118,428 | 0 |
| 31 Mar 17 | 215,873 | 5,508 | 124,424 | 0 |
| 31 Dec 16 | 216,952 | 5,146 | 124,239 | 0 |
| 30 Sep 16 | 217,393 | 5,210 | 125,192 | 0 |
| 30 Jun 16 | 221,916 | 4,383 | 127,340 | 0 |
| 31 Mar 16 | 215,016 | 2,909 | 124,166 | 0 |
| 31 Dec 15 | 217,844 | 3,087 | 127,580 | 0 |
| 30 Sep 15 | 220,071 | 2,953 | 131,814 | 0 |
| 30 Jun 15 | 224,602 | 3,495 | 136,349 | 0 |
| 31 Mar 15 | 221,210 | 2,112 | 133,677 | 0 |
| 31 Dec 14 | 222,302 | 2,661 | 132,164 | 0 |
| 30 Sep 14 | 218,897 | 4,334 | 127,283 | 0 |
| 30 Jun 14 | 217,312 | 5,149 | 129,740 | 0 |
| 31 Mar 14 | 203,505 | 6,323 | 125,228 | 0 |
| 31 Dec 13 | 192,556 | 6,196 | 119,415 | 0 |
| 30 Sep 13 | 185,340 | 3,610 | 116,598 | 0 |
| 30 Jun 13 | 170,047 | 3,464 | 106,520 | 0 |
Quality Earnings: PYFA is currently unprofitable.
Growing Profit Margin: PYFA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PYFA is unprofitable, but has reduced losses over the past 5 years at a rate of 37.4% per year.
Accelerating Growth: Unable to compare PYFA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PYFA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10.1%).
Return on Equity
High ROE: PYFA has a negative Return on Equity (-23.87%), as it is currently unprofitable.